Telomerase-mediated telomere-modifying compounds

摘要

The present disclosure relates to pharmaceutical compositions and methods using 6-mercaptopurine riboside or analogs thereof for the treatment of cancer and other hyperproliferative diseases. The described compounds can be converted in vivo to telomeric substrates and can be recognized by telomerase for incorporation into telomeres of telomerase-active cells, thereby leading to induction of cell death in telomerase-active cells. [Selection figure] None